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Opinion statement
Despite numerous case reports, the evidence for treatment of bruxism is still low.
Different treatment modalities (behavioral techniques, intraoral devices, medica-
tions, and contingent electrical stimulation) have been applied. A clinical evalu-
ation is needed to differentiate between awake bruxism and sleep bruxism and
rule out any medical disorder or medication that could be behind its appearance
(secondary bruxism). A polysomnography is required only in a few cases of sleep
bruxism, mostly when sleep comorbidities are present. Counselling with regard to
sleep hygiene, sleep habit modification, and relaxation techniques has been
suggested as the first step in the therapeutic intervention, and is generally
considered not harmful, despite low evidence of any efficacy. Occlusal splints
are successful in the prevention of dental damage and grinding sounds associated
with sleep bruxism, but their effects on reducing bruxism electromyographic
(EMG) events are transient. In patients with psychiatric and sleep comorbidities,
the acute use of clonazepam at night has been reported to improve sleep
bruxism, but in the absence of double-blind randomized trials, its use in general
clinical practice cannot be recommended. Severe secondary bruxism interfering
with speaking, chewing, or swallowing has been reported in patients with neu-
rological disorders such as in cranial dystonia; in these patients, injections of
botulinum toxin in the masticatory muscles may decrease bruxism for up to 1–
5 months and improve pain and mandibular functions. Long-term studies in larger
and better specified samples of patients with bruxism, comparing the effects of
different therapeutic modalities on bruxism EMG activity, progression of dental
wear, and orofacial pain are current gaps of knowledge and preclude the devel-
opment of severity-based treatment guidelines.
* The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
Bruxism is an oral motor condition which has raised
interest in dental, sleep, and neurological research in the
last 10 years, with more than 1200 articles published in
MEDLINE including 151 review papers. Studies about
prevalence, risk factors, pathophysiology, and current
and new experimental therapies had important reper-
cussions on treatment decisions.
Recently, an international expert commission has
redefined bruxism as repetitive jaw muscle activity char-
acterized by clenching or grinding of the teeth and/or by
bracing or thrusting of the mandible that can occur
during wakefulness (i.e., awake bruxism) or during sleep
(i.e., sleep bruxism) [1••]. Awake bruxism is usually
seen as a jaw clenching habit that appears in response
to stress and anxiety states [2], while sleep bruxism
represents a sleep related rhythmic masticatory activity
generally associated with arousals (from sleep) [3, 4].
Both awake and sleep bruxism are sub classified into
either primary, not related to any other medical condi-
tion, or secondary, associated to neurological disorders or
considered an adverse effect of drugs [5–8].
Based on face-to-face questionnaires and telephone
interviews, the prevalence of sleep bruxism (i.e., teeth
grinding episodes during sleep) has been estimated
around 8 % of the adult population and gradually de-
creases with aging [9, 10]. When both questionnaires and
polysomnographic (PSG) criteria are considered, the prev-
alence is slightly lower with 5.5 %, as indicated byMaluly
et al. in a sample of 1042 individuals [11••]. Regarding
awake bruxism, around 20 % of the general population
report awareness of pressing their teeth together, with
predominance in females [12]. There is no available data
in relation to prevalence of secondary bruxism, and most
of the literature derives from cases reports.
Bruxism can lead to dental wear, jaw muscle pain and
fatigue, and temporal headaches, and in some severe
forms can compromise oral functions such as chewing,
speaking, and swallowing [13]. However, no direct rela-
tionship has been observed between the type of bruxism,
the severity, and the presence of additional clinical signs
and symptoms. In fact, it has been reported that patients
with frequent sleep bruxism are less prone to complain
about fatigue and pain in the masticatory muscles than
the patients with fewer masticatory events per night [14].
Awake bruxism is usually identified by the patient, but
there are no objective methods that reliably quantify this
behavior. In contrast, the American Academy of Sleep
Disorders has proposed both clinical and PSG criteria for
diagnosing sleep bruxism [15]. These advances in its mea-
surement have helped to launch several randomized clin-
ical trials (RCT) for evaluating the effects of different
therapies on reducing the masticatory activity during
sleep.
The aim of this article is to review the therapeutic
approaches for treating bruxism and clarify the current
evidence.
Methods
A literature search was performed using MEDLINE/PubMed database, com-
bining the terms Bbruxism^ OR Bteeth grinding^ OR Bclenching^ AND
Btreatment^ as the first step in the research strategy. All abstracts in English were
screened. We first selected RCT performed in adults older than 18 years with a
clinical or PSG diagnosis of bruxism (awake bruxism and/or sleep bruxism),
independently if they had or not comorbid sleep, neurological, or psychiatric
disorders. Nonrandomized comparative studies, pre-treatment/post-treatment
studies, cohort studies, and case reports were considered in case of scarce or
lacking RCT.
Primary bruxism
Effectivemanagement of primary awake bruxism is challenging. Since increased
anxiety levels and somatization symptoms have been reported in these patients
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[16, 17], interventions such as counselling about triggers, habits modification,
relaxation therapy, or biofeedback have been suggested to be appropriate [18].
However, no RCT exist to support these approaches.
In contrast to awake bruxism, several RCT have been performed to investi-
gate the efficacy of different treatments in the reduction of bruxism activity
during sleep. Most of them showed heterogeneous results. The treatments
evaluated are as follows: (1) sleep hygiene measures combined with relaxation
techniques, (2) splint therapy, (3) pharmacological therapy, and (4) contingent
electrical stimulation. For further details, see Table 1.
Sleep hygiene measures combined with relaxation techniques
The treatment of sleep bruxism usually begins with counselling of the patient
with regard to sleep hygiene. This includes stop smoking and drinking of coffee
or alcohol at night, limit the physical or mental activity before going bed, and
ensure good bedroom conditions (quiet and dark). There is only one RCT that
evaluated the effect of 4 weeks of sleep hygiene measures combined with
relaxation techniques on sleep bruxism (as shown by PSG), but failed to find
significant differences in comparison to baseline [34•]. Besides this negative
result and the lack of evidence with other behavioral approaches, it is still
reasonable to recommend good sleep hygiene in clinical practice, especially
considering that alcohol, tobacco, and coffee consumption are risk factors for
sleep bruxism [10, 35•] and that sensitivity to stress is commonly reported by
the patients [36].
Splint therapy
Occlusal splints have been considered as the first-line strategy for preventing
dental grinding noise and tooth wear in primary sleep bruxism [37]. In general,
the design of the device is simple, covers the whole maxillary or mandibular
dental arch, and is well tolerated by the patient. However, its efficacy reducing
the number of masticatory episodes per hour of sleep seems to be transient,
with a maximal effect observed during the first 2 weeks [19], and returning to
baseline after longer periods of use [20, 21, 24]. Only one study have compared
occlusal splints versus a medication doses gabapentin, and found that both
treatments reduced similarly the muscle activity associated with sleep bruxism
after 2 month of therapy [25].
Albeit rare, occlusal splints may worsen respiration during sleep in patients
with obstructive sleep apnea (OSA) and thus, special care should be taken when
treating sleep bruxism in this population [38]. In the absence of larger studies
that confirm this adverse effect, a mandibular advancement device might be an
alternative treatment in patients with concomitant OSA and sleep bruxism,
because it decreases both the number of sleep respiratory events in OSA and the
sleep-related masticatory activity in sleep bruxers [22, 23, 39••, 40]. Again, to
generalize this indication, more research needs to be done.
Pharmacological therapy
Most of the drugs investigated for treating sleep bruxism were used in experi-
mental studies of small sample size and in which the effects were solely
evaluated after very short treatment periods using the medication. Mohamed
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et al. reported the first RCT evaluating amitriptyline (used during 7 days) in a
group of patients with sleep bruxism and temporomandibular disorder symp-
toms, and found no changes in pain reports and in the nocturnal masseteric
muscle activities with the therapy [26]. In contrast, Lobbezzo et al. evaluated the
acute effect of levodopa in 10 severe sleep bruxers and found a decrease in the
number of sleep-related masticatory events in 7 of them when compared to
placebo. However, given the unknown clinical relevance and the lack of further
research supporting its use, levodopa is not considered as a treatment for sleep
bruxism [27]. Other pharmacological therapies such as bromocriptine and
propranolol have also been investigated, but again failed to show positive
results [28, 29].
On the other side, an experimental one-night treatment with clonidine, an
α2 adrenergic agonist used for treating hypertension, attention-deficit hyperac-
tivity disorder in children, and for acute alcohol or substanse withdrawal
syndrome, has demonstrated to reduce bruxism activity by 60 %, but with
significant adverse effects such as morning hypotension, REM sleep suppres-
sion, and dry mouth [29]. In patients with psychiatric and sleep comorbidities,
the acute use of clonazepam has been reported to improve sleep bruxism
activity together with the general quality of sleep, as suggested by Saletu et al.
[41, 42]. However, these results are based on single-blind nonrandomized
trials. To finally recommend both clonidine and clonazepam in the clinical
routine, high-quality double-blinded RCT with larger sample size, different
adjustable doses and larger duration, systematic assessment of adverse events,
and perhaps also withdrawal studies are needed.
Recently, some studies have evaluated the efficacy of botulinum toxin type A
injections into the masticatory muscles for treating sleep bruxism. Based on
PSG, Shim et al. found that the amplitude of the muscle contraction during
bruxism events was reduced after 4 weeks of injection, but with no changes in
the rhythm or number of bruxism episodes per hour of sleep [30••]. Lee et al.
reported similar results in an ambulatory EMG-based study over 8 to 12 weeks
after botulinum toxin injection; however, no differences were observed in the
relief of teeth grinding sounds and morning jaw stiffness in comparison to
saline injections at any time of the study [31]. More RCT comparing the effect of
botulinum toxin, saline injections, and dry needling are needed to clarify if
botulinum toxin is useful in the management of sleep bruxism with and
without orofacial pain.
Contingent electrical stimulation
In the last years, contingent electrical stimulation (CES) has reappeared in an
attempt to reduce the masticatory muscle activity associated to sleep bruxism.
The rationale for CES consists in the inhibition of the masticatory muscles
responsible of bruxism, applying a low-level electrical stimulation on the
muscles when they become active, i.e. during the bruxism episode. Two ex-
perimental studies have applied CES in patients with signs and symptoms of
sleep bruxism andmyofascial pain, and found a reduction of the EMG episodes
per hour of sleep while using CES, but with no changes in pain and muscle
tension scores [32, 33]. Raphael et al. confirmed these results in a group of
women with sleep bruxism and myofascial pain, but in addition showed that
the efficacy of CES in reducing nocturnal bruxism events was confined to active
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periods and not after discontinuing the device [43]. Even if these results are
promising, the unknown effect on tooth wear and the low impact on pain
symptomsmay limit the generalization of its use. Additional studies evaluating
long-term treatment periods, the impact of contingent versus sustained electri-
cal stimulation, and the combination with other therapies are still needed.
Bruxism associated with neurological disorders
Bruxism has been documented in the context of some neurological disorders,
mostly in form of case reports. Clinically, an acute onset of severe teeth grinding
that occursmainly duringwakefulness and that cannot be prevented voluntarily
should alert the clinician about the secondary etiology of bruxism. Moreover, it
usually accompanies typical hallmarks of the underlying disease. For example,
some patients with cranial and cervical dystonia show severe awake teeth
grinding in combination with dystonic/dyskinetic movements in other parts of
the face [44, 45]; in two patients with drug-resistant temporal lobe epilepsy,
long-lasting teeth grinding episodes were the main features of the seizures, and
usually preceded other typical signs such as the loss of consciousness and the
limbs automatisms [46•, 47]; and in three women suffering from Huntigton’s
disease, Tan et al. reported a persistent awake teeth grinding that worsened with
the progression of the disease [13].
The management of bruxism associated with neurological disorders focuses
on improvement of chewing, speaking, swallowing, and feeding, which are
severely compromised, and to relieve orofacial pain symptoms. However, no
general rules can be applied because placebo-controlled studies are lacking, so a
case-by-case approach is suggested. Conservative measures such as occlusal
splints and the use of drugs for treating the underlying disease may help the
patient to control his bruxism; for example, a single case report in a patient with
multiple system atrophy and constant awake teeth grinding claimed a marked
improvement 1 week after starting levodopa-carbidopa, while similar results
were documented after using galantamine in a patient with Alzheimer disease
and awake bruxism [48, 49]. Injections of botulinum toxin in the masticatory
muscles have been used in two case series of patients with severe bruxism
associated with cranial dystonia and other movement disorders [44, 50]. In
these studies, the therapy rendered the patients free of bruxism for up to 1–
5 months and markedly improved pain reports and mandibular functions.
Botulinum toxin was also effective in the resolution of bruxism that appeared
during the recovering from coma in four patients with anoxic or traumatic brain
injury [51–54]. Finally, surgical treatment of temporal lobe epilepsy resolved
the occurrence of ictal bruxism in two reported cases [46•, 47]. It should be
mentioned that intraoral devices should be used with caution in epilepsy
patients as splints can break during seizures and obstruct the airway. A summary
of the diseases with concomitant bruxism and the therapeutic approach is
shown in Table 2.
Bruxism as an adverse effect of medications
A large number of clinical case reports have described the appearance of
bruxism as an adverse effect of medications. Generally speaking, mostly













































































































































































































































































































































































































































































































































































































































































































































































































































































































10 Page 10 of 15 Curr Treat Options Neurol (2016) 18: 10
middle-aged women with a wide spectrum of psychiatric disorders developed
awake and/or sleep bruxism few weeks after starting the medicament. Patients
or bed partners reported that bruxism augmented or decreased in accordance
with dose manipulation and that in some cases definitely disappeared with
drug withdrawal. Second-generation antidepressants have been the more cited
drugs prone to cause (or exacerbate in some cases) bruxism, further followed by
antipsychotics or bupropion. The list of medicaments associated with bruxism
is shown in Table 3.
Regarding the clinical management, some authors have suggested to Bwait
and see^ for 1 month because spontaneous remission may occur [62]. If the
problem persists, a reduction of dose or change of medication may alleviate or
even resolve the problem [57–59, 73, 79], although a definitive cease might be
expected with drug withdrawal [58, 63, 66, 72, 74, 75, 79, 81]. In those cases in
which the psychiatric symptoms have been successfully improved with the
current medication and no changes are planned, some authors have co-
prescribed buspirone [57, 64, 71, 72, 75, 76], tandospirone [68], or
gabapentine [65, 69, 77], reporting a complete cease of bruxism. However,
caution mast be taking with the generalization of these findings, since case
reports cannot establish cause-effect relationships and are susceptible to pub-
lication bias and over-interpretation. Based on these premises, costs and bene-
fits of the drug manipulation should be considered individually and always
performed by physicians. Moreover, polysomnographic and placebo-
controlled studies evaluating the effects of antidepressants and other drugs on
the occurrence of bruxism-like behavior require further research.
Conclusion
In the absence of a causal treatment, the management of bruxism focuses to
prevent progression of dental wear, reduce teeth grinding sounds, and improve
muscle discomfort and mandibular dysfunction in the most severe cases.
Counselling and behavioral strategies, splint therapy, medications, and con-
tingent electrical stimulation have shown heterogeneous results in resolving the
EMG events associated with sleep bruxism, and most of the RCT did not
Table 3. Bruxism as an adverse effect of medication
Medication Citation






Serotonin and noradrenaline reuptake inhibitors
Duloxetine [72]
Venlafaxine [59, 73–78]
Dopamine and noradrenaline reuptake inhibitors [79]
Antipsychotics [80, 81]
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evaluate the effects on other symptoms such as pain or tooth wear progression.
Long-term studies with a wide severity spectrum of sleep bruxism patients, and
comparing the effect of different treatments should be performed to elucidate
the importance of each intervention in the resolution of the signs and symp-
toms commonly referred by the patients. The choice of not treating bruxism
must also be further explored, at least in asymptomatic patients with only mild
dental wear. Even more must be done to successfully treat awake bruxism, in
which RCTs are still lacking.
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